AOD-9604 Doesn't Work Like You Think

You've probably seen AOD9604 on a clinic menu or on a research company website, and they're calling it a targeted fat burning peptide.

The pitch is clean and simple, promising the fat loss benefits of growth hormone without the baggage that comes with it. So it doesn't raise your IGF-1, it doesn't mess with your blood sugar, and it doesn't cause water retention.

And that all sounds great, but this compound went through six human clinical trials with over 900 participants, and the largest one failed. I cannot point you to a study confirming that exact participant count myself, so take the number as what circulates in the AOD literature rather than something I can put a citation on, but the failure of the biggest trial is well documented and the company that developed it ended up shutting down the entire obesity program.

And the way that people are actually using it today, which is a subcutaneous injection, was never tested in any of these trials.

All right, so to understand why AOD9604 exists, you need to first understand the problem that it was designed to solve.

Growth hormone is one of the strongest fat mobilizing hormones your body makes. Give someone enough of it for long enough and body fat goes down and lean mass goes up, which is exactly what the metabolic literature on GH administration describes.

But full growth hormone carries a list of problems that make it a bad fit for a lot of people. It raises IGF-1, which can accelerate tumor growth, it causes insulin resistance over time, it causes water retention and carpal tunnel, and in extreme cases, it can cause organ growth.

None of that is speculation, since acromegaly, where the pituitary pumps out growth hormone unchecked for years, shows you the jaw and hands and heart enlarging, and the whole clinical picture of the disease is built on what chronically elevated GH does to tissue. The insulin resistance piece has its own mechanism, where growth hormone interferes with insulin signaling at the cellular level and pushes blood sugar up over time. And carpal tunnel shows up often enough in acromegaly patients that it has been written about as its own case series, because the swelling in the wrist compresses the nerve.

So researchers in Australia looked at that molecule and asked a reasonable question. What if we could isolate just the piece responsible for fat burning and strip away everything else? So what they did is they cut out amino acids 176 through 191 from the tail end of the growth hormone molecule, and then they added a tyrosine substitution to stabilize it, and they called it anti-obesity drug 9604.

Keep the lipolytic tail, the researchers reasoned, and throw away the part of the molecule that talks to the liver and the receptors that drive the side effects.

And by the way, you're also gonna see HGH fragment 176 through 191 sold online as though it's the same thing. It is related, but it is not identical.

AOD 9604 is the engineered more stable version, and even the more stable version couldn't beat placebo in its biggest trial. So buying the raw fragment because you think it hits harder means you are starting from a less stable position than the version that already failed.

Now, the mechanism that AOD 9604 works through is something called beta-3 adrenergic receptor activation, which is a receptor on the surface of fat cells that, when switched on, tells the cell to start releasing stored fat. The honest caveat is that this mechanism comes mostly from animal and cell work, and no study has shown it cleanly in humans at the doses people inject.

That is the entire job this fragment does, nothing more.

It doesn't raise your IGF-1, though I should be clear that the research hasn't given us a full human picture of every hormonal readout at injection doses either. It doesn't suppress appetite, it doesn't build muscle, it doesn't improve your sleep, and it doesn't help you recover.

A single fragment carved off a much larger molecule, built to do exactly one thing.

Before the trial data makes sense, you need the full picture of how growth hormone actually burns fat, because the fragment only looks impressive when you forget what it was cut out of.

Growth hormone works through two separate pathways in your body.

Growth hormone itself acts directly, reaching your fat cells before it ever touches your liver and breaking stored triglycerides down into free fatty acids so you can burn them for fuel. In my experience the mechanistic detail people repeat about the exact enzyme step happens before hepatic conversion is cleaner than the literature actually is, so treat it as the shape of the process rather than a settled sequence.

What matters practically is that the effect gets stronger when insulin is low, which is why fasted dosing before bed is the standard recommendation for anything that raises your own growth hormone.

The second pathway takes a longer route, working indirectly through your liver. Growth hormone travels there and converts to IGF-1, and IGF-1 is what drives muscle protein synthesis, recovery, collagen production, bone density, and cognitive function. IGF-1 also contributes to fat breakdown on its own.

So you get lipolysis at stage one, lipolysis again at stage two, and every other downstream benefit riding along with it.

And when you use a secretagog like CJC1295 and ipamarylin, what you're doing is you're triggering your own pituitary to release actual growth hormone. Hold onto that, because it decides the entire argument in about ninety seconds.

Here is what actually happened when they tested AOD9604 in humans, and it's where the whole thing falls apart.

Genetically obese mice and Zucker rats given the compound lost meaningful body weight in early testing, fat oxidation climbed, and blood sugar and IGF-1 stayed put, a result promising enough on its own to justify moving into people.

The phase two alpha trial ran roughly 300 obese adults on oral tablets once daily for 12 weeks across six dose groups. The one milligram group lost 2.6 kilograms against 0.8 kilograms on placebo, which cleared statistical significance, and the company was excited.

But the shape of the result was wrong. The dose response curve was inverted, which means the lowest dose performed the best and the highest dose performed the worst.

People on 10 milligrams lost less weight than people on 1 milligram. When you test a drug, more drug should mean more effect, and when the smallest dose wins in a study that size, you are looking at something that might be noise wearing a lab coat.

Undeterred, the company moved into a second and larger trial, the option study, phase two B. And 536 obese adults over 24 weeks were tested taking the same oral tablets, this time across three dose groups plus placebo.

Every single dose group finished the trial statistically indistinguishable from placebo, and development was terminated in 2007 with the obesity program closed for good.

I want to be fair about why that might have happened. All six human trials used oral tablets, and peptides are hard to deliver orally because stomach acid and digestive enzymes tear them apart before absorption, so bioavailability was probably a real limitation.

That gap, between a failed oral trial and an untested injectable version, is exactly what modern clinics are selling into. So when a clinic tells you that injectable AOD 9604 is gonna burn your stubborn belly fat, what they're doing is they're taking animal data, skipping past a failed human trial, and then applying it to a delivery method that was never studied in humans.

It stays on menus because it is almost impossible to get hurt by, which means almost no liability, and because the name sounds like it came out of a pharmaceutical pipeline rather than a supplement catalog.

But one thing to note about this is AOD 9604 actually got so popular that the FDA decided to bring it before their advisory committee in December of 2024, to review whether compounding pharmacies should be allowed to keep making it. Their vote landed against it.

But despite all that, here is what I actually think the biggest problem is with AOD 9604.

There is a lot more of this inside the free community, and it is genuinely free, so if you want somewhere to ask the follow-up question the men's group is here: https://www.skool.com/jh-iron-forge-brotherhood/about

Research notes: Dineen R, Stewart PM, and Sherlock M covered acromegaly in QJM in 2017. Sharma R, Kopchick JJ, Puri V, and colleagues examined the effect of growth hormone on insulin signaling in Mol Cell Endocrinol in 2020. Yarasheski KE reviewed growth hormone effects on metabolism, body composition, muscle mass, and strength in Exerc Sport Sci Rev in 1994. Imamura H, Isu T, Iwasaki Y, and colleagues documented carpal tunnel syndrome in acromegaly in Hokkaido Igaku Zasshi in 1989.

References:

Dineen R, Stewart PM, Sherlock M. Acromegaly. QJM. 2017. https://pubmed.ncbi.nlm.nih.gov/26873451/

Sharma R, Kopchick JJ, Puri V et al.. Effect of growth hormone on insulin signaling. Mol Cell Endocrinol. 2020. https://pubmed.ncbi.nlm.nih.gov/32966863/

Yarasheski KE. Growth hormone effects on metabolism, body composition, muscle mass, and strength. Exerc Sport Sci Rev. 1994. https://pubmed.ncbi.nlm.nih.gov/7925547/

Díez JJ, Gómez-Pan A. [New physiological and pharmacological aspects of the growth hormone (II). Therapeutic applications in adults]. Rev Clin Esp. 1993. https://pubmed.ncbi.nlm.nih.gov/8497741/

Imamura H, Isu T, Iwasaki Y et al.. [Carpal tunnel syndrome in acromegaly--4-case report and review of literature]. Hokkaido Igaku Zasshi. 1989. https://pubmed.ncbi.nlm.nih.gov/2591876/